Jason Baker is an Infectious Disease physician. ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
701 Park Ave # P7
Minneapolis, MN 554151623
Telephone
612-873-2700Registry record last updated 28 Sept 2012.
Clinical trials
- Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
Sponsor: University of Minnesota
- Preoperative Melatonin to Decrease Analgesia Usage After Third Molar Surgery
Sponsor: Montefiore Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
34.4%Statin12.9%Rosuvastatin Calcium56%Atorvastatin Calcium44%Part D<11 patientsAngiotensin receptor blocker (ARB)6.3%Losartan Potassium75%Valsartan26%Part D<11 patients+ 6 more classes in this area
Anti-infectives
24.7%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor11.3%Descovy69%Triumeq31%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor10.2%Tivicay84%Dovato16%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
12.3%Proton pump inhibitor8.1%Omeprazole70%Pantoprazole Sodium30%Part D<11 patientsBiguanide (metformin)2.7%Metformin Hcl100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
6 NIH research awards on record, funded 2014–2025 per NIH RePORTER. The latest:
- Immunologic basis of cardiac disease after severe COVID-19
University of Minnesota
FY2025$662,793R01HL158756 - Immunologic basis of cardiac disease after severe COVID-19
University of Minnesota
FY2024$671,068R01HL158756 - Clinical and immunologic factors underlying heart failure with preserved ejection fraction among persons with HIV in South Africa
Hennepin Healthcare Research Institute
FY2024$513,760R01HL160437
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”